Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM
Postprandial glucose excursions with sotagliflozin in patients with... | Download Scientific Diagram
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure | NEJM
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM
Frontiers | Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis
The inTandem 2 study: 52-week efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in adults with type 1 diabetes - Media Centre | EASD
Sotagliflozin reduces deaths, time spent in hospital for some patients with diabetes
Summary of cardiovascular outcome trials with sodium-glucose... | Download Scientific Diagram
Cardiac, renal, and metabolic effects of sodium–glucose co‐transporter 2 inhibitors: a position paper from the European Society of Cardiology ad‐hoc task force on sodium–glucose co‐transporter 2 inhibitors - Herrington - 2021 -
Lexicon Fires Back after Sanofi Ends Up-to-$1.7B Diabetes Collaboration
JDRF-T1D Win: Zynquista Approved in Europe for Type 1 Diabetes
Herzinsuffizienz | Sotagliflozin bei Diabetes mellitus Typ 2 und Herzinsuffizienz | springermedizin.de
57th EASD: Sotagliflozin for Type 2 Diabetes --SGLT 1/2 inhibitor
Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/ 2 inhibitor - Pablo Lapuerta, Brian Zambrowicz, Paul Strumph, Arthur Sands, 2015
Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/ 2 inhibitor - Pablo Lapuerta, Brian Zambrowicz, Paul Strumph, Arthur Sands, 2015
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks - The Lancet Diabetes & Endocrinology
Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives | Cardiovascular Diabetology | Full Text
SCORED/SOLOIST: Dual inhibitor provides benefits in type 2 diabetes and heart failure, CKD
A Type 1 Diabetes Pill? Newest Sotagliflozin Trial Results
Sotagliflozin with Insulin therapy prevents DKA in young Type 1 Diabetics: Study
The inTandem 2 study: 52-week efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in adults with type 1 diabetes - Media Centre | EASD
Sotagliflozin reduces hospitalizations and urgent visits for patients with diabetes and worsening heart failure | 2 Minute Medicine
Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment - ScienceDirect
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes | NEJM
